Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Comparative in-Vitro Efficacy of CD20xCD3 IgG Bispecific Biosimilar Constructs Against Diffuse Large B Cell Lymphoma (DLBCL) Cell Lines with Different Levels of Expression of CD20

Joshua S. Bray, Gethin R. Thomas, Victoria M. Smith, Sandrine Jayne, Martin J.S. Dyer, Harriet S. Walter

Blood (2024) 144 (Supplement 1): 5826.

https://doi.org/10.1182/blood-2024-203884

Published: 2024

Journal Articles

ASTX295 a Novel Potent MDM2 Antagonist Induces More Than One Mechanism of Programmed Cell Death (PCD) in Lymphoid Malignancies

Nishat Iqbal, Sandrine Jayne, Harriet S. Walter, Andrea Biondo, Martin Sims, Maria Ahn, Martin J.S. Dyer

Blood (2024) 144 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2024-206110

Published: 2024

Journal Articles

Establishment of an In Vivo Mouse Model to Study and Overcome Infusion Related Reactions Associated with Fcgriib Antibody Administration

Ingrid Karlsson, PhD, Linda Mårtensson, PhD, Marie Borggren, PhD, Mathilda Kovacek, Carl Roos, Therese Blidberg, Robert Oldham, PhD, Mats Jerkeman, MD PhD, Martin J.S. Dyer, MD PhD, Andrew Davies, MD PhD, Raul Córdoba, MD PhD, Pau Abrisqueta, MD PhD, Stephen Beers, PhD, Ingrid Teige, PhD, Andres McAllister, MD PhD, Sean H Lim, MD PhD, Mark S Cragg, PhD, Björn Frendéus, PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138658

Published: 2020

Journal Articles

Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia

Blood (2019) 134 (Supplement_1): 1740.

https://doi.org/10.1182/blood-2019-122037

Published: 2019

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Alexey V Danilov, MD PhD, Charles Herbaux, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Simon Rule, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Lionel Karlin, MD, Christopher Fegan, MD

Blood (2018) 132 (Supplement 1): 3135.

https://doi.org/10.1182/blood-2018-99-113111

Published: 2018

Journal Articles

Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis

Richard Dillon, MA, PhD MRCP, FRCPath, Jelena Jovanovic, PhD, Nicola Potter, PhD, Nicola Foot, MSc, Matthew J Ahearne, MD MBBS, Sandrine Jayne, PhD, Michael Dennis, MD MRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Martin J.S. Dyer, Paresh Vyas, Lynn Quek, FRCPath, DPhil, MBBS, Nigel H. Russell, Robert K. Hills, MA, DPhil, MSc, Ellen Solomon, PhD, David Grimwade, PhD MRCP, MRCPath

Blood (2018) 132 (Supplement 1): 2570.

https://doi.org/10.1182/blood-2018-99-114233

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Gilles Salles, MD PhD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Daniel James Hodson, MD PhD, Krimo Bouabdallah, MD, Loic Ysebaert, MD PhD, Guillaume Cartron, Andrew John Davies, PhD, Alexey V Danilov, MD PhD, Christopher Fegan, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Franck Morschhauser, MD

Blood (2018) 132 (Supplement 1): 5344.

https://doi.org/10.1182/blood-2018-99-113115

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Franck Morschhauser, MD, John Radford, MD FRCP, Loic Ysebaert, MD PhD, Stephen E Spurgeon, MD, Ebenezer A Kio, MD, Gilles Salles, MD PhD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 5345.

https://doi.org/10.1182/blood-2018-99-113117

Published: 2018

Journal Articles

Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

Ian W. Flinn, MD PhD, John G. Gribben, MDDSc FMedSci, Martin J.S. Dyer, William G Wierda, MD PhD, Michael B. Maris, Richard R. Furman, MD, Peter Hillmen, MBChB, PhD, Jeffrey Jones, MD, Swami P. Iyer, MD, Surai Jones, Yanwen Jiang, Daniela Soriano Pignataro, Kathryn Humphrey, Mehrdad Mobasher, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 430.

https://doi.org/10.1182/blood.V130.Suppl_1.430.430

Published: 2017

Journal Articles

Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies

Gilles A. Salles, Franck Morschhauser, Bruce Cheson, MD, Simon A. Rule, MD, Christopher Fegan, Cartron Guillaume, Cara Nelson, Yingsi Yang, Siddhartha Mitra, Alexander Starodub, Martin J.S. Dyer

Blood (2016) 128 (22): 2961.

https://doi.org/10.1182/blood.V128.22.2961.2961

Published: 2016

Journal Articles

Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia

Harriet S. Walter, Sandrine Jayne, Simon A. Rule, MD, Guillaume Cartron, MD PhD, Franck Morschhauser, Christopher Fegan, Yingsi Yang, Siddhartha Mitra, Martin J.S. Dyer, Gilles A. Salles

Blood (2016) 128 (22): 3233.

https://doi.org/10.1182/blood.V128.22.3233.3233

Published: 2016

Journal Articles

Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

Ian W. Flinn, MD PhD, Mark Brunvand, MD, Michael Y. Choi, MD, Martin J.S. Dyer, Prof., John Gribben, MDDSc, Peter Hillmen, MB, ChB, PhD, Jeffrey Jones, MD MPH, Yan Li, Mehrdad Mobasher, Gregory Vosganian, Thomas J. Kipps, MD, PhD

Blood (2015) 126 (23): 494.

https://doi.org/10.1182/blood.V126.23.494.494

Published: 2015

Journal Articles

Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia

Blood (2015) 126 (23): 365.

https://doi.org/10.1182/blood.V126.23.365.365

Published: 2015

Journal Articles

Mass Cytometry Analysis Dissects CRLF2-Driven Signaling Pathways in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Jolanda Sarno, Kara L. Davis, DO, Angela Maria Savino, PhD, Cristina Bugarin, Stefania Pinto, Chiara Buracchi, PhD, Astraea Jager, BS, Chiara Palmi, PhD, Ruth C Barber, PhD, Daniela Silvestri, Gianni Cazzaniga, PhD, Martin J.S. Dyer, Prof., Andrea Biondi, Prof, MD, Garry P. Nolan, Prof, PhD, Giuseppe Gaipa, PhD

Blood (2015) 126 (23): 906.

https://doi.org/10.1182/blood.V126.23.906.906

Published: 2015

Journal Articles

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

Anna Skowronska, Gulshanara Ahmed, Ceri E Oldreive, PhD, David Oscier, MD, Anton Parker, Martin J.S. Dyer, MA, DPhil, Estella Matutes, MD, PhD, A. Malcolm R Taylor, PhD, Paul AH Moss, MD PhD, Tatjana Stankovic, MD PhD

Blood (2011) 118 (21): 467.

https://doi.org/10.1182/blood.V118.21.467.467

Published: 2011

Journal Articles

A Variety of T-Cell Subsets Contribute to CD4+ T-Cell Infiltration in Diffuse Large B-Cell Lymphoma and Both Total CD4+ and CD4+FoxP3+ T-Cell Numbers Predict Clinical Outcome,

Matthew J Ahearne, MBChB MRCP, Kaljit S Bhuller, MBChB MRCP, Roger Hew, MBChB, Giovanna Roncador, Martin J.S. Dyer, MA, DPhil, Daniel B. Kennedy, Fiona Miall, MD, Simon D. Wagner, MBBS, PhD, FRCP

Blood (2011) 118 (21): 3684.

https://doi.org/10.1182/blood.V118.21.3684.3684

Published: 2011

Journal Articles

Protein Profiling of Plasma Membranes and Lipid Rafts Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma

Robert S Boyd, PhD, Rebekah Jukes-Jones, PhD, Renata Walewska, FRCP, David Brown, PhD, Martin J.S. Dyer, MA, DPhil, FRCP, Kelvin Cain, PhD

Blood (2008) 112 (11): 374.

https://doi.org/10.1182/blood.V112.11.374.374

Published: 2008

Journal Articles

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Blood (2008) 112 (11): 328.

https://doi.org/10.1182/blood.V112.11.328.328

Published: 2008

Journal Articles

Targeting Autophagy Potentiates Imatinib-Induced Cell Death in Philadelphia Positive Cells Including Primary CML Stem Cells.

Blood (2008) 112 (11): 1070.

https://doi.org/10.1182/blood.V112.11.1070.1070

Published: 2008

Journal Articles

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.

Blood (2007) 110 (11): 2348.

https://doi.org/10.1182/blood.V110.11.2348.2348

Published: 2007

NARROW

Comparative in-Vitro Efficacy of CD20xCD3 IgG Bispecific Biosimilar Constructs Against Diffuse Large B Cell Lymphoma (DLBCL) Cell Lines with Different Levels of Expression of CD20

ASTX295 a Novel Potent MDM2 Antagonist Induces More Than One Mechanism of Programmed Cell Death (PCD) in Lymphoid Malignancies

Establishment of an In Vivo Mouse Model to Study and Overcome Infusion Related Reactions Associated with Fcgriib Antibody Administration

Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies

Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia

Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia

Mass Cytometry Analysis Dissects CRLF2-Driven Signaling Pathways in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

A Variety of T-Cell Subsets Contribute to CD4+ T-Cell Infiltration in Diffuse Large B-Cell Lymphoma and Both Total CD4+ and CD4+FoxP3+ T-Cell Numbers Predict Clinical Outcome,

Protein Profiling of Plasma Membranes and Lipid Rafts Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Targeting Autophagy Potentiates Imatinib-Induced Cell Death in Philadelphia Positive Cells Including Primary CML Stem Cells.

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only